Clinical Trials
295
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (194 trials with phase data)• Click on a phase to view related trials
Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy
- Conditions
- High - Risk NMIBC
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT07053748
Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT07053722
An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer
- Interventions
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT07053735
A Randomized Controlled Trial of Five - Flavor Sophora Flavescens Enteric - Coated Capsules for Radiation - Induced Proctitis After Pelvic Radiotherapy
- Conditions
- Radiation - Induced Proctitis
- Interventions
- Drug: five - flavor sophora flavescens enteric - coated capsules plus glutamine and warm - water sitz bathsDrug: glutamine and warm - water sitz baths
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT07053761
Remimazolam and Emergence Delirium in Pediatrics
- Conditions
- PediatricNeurosurgeryEmergence DeliriumRemimazolamSevoflurane Anesthesia
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 248
- Registration Number
- NCT07046364
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 58
- Next
News
Cellular Senescence Gene Signature Reveals New Biomarkers for Idiopathic Pulmonary Fibrosis
Researchers identified four key cellular senescence-related genes (CDKN2A, VEGFA, SOX2, and FOXO3) that could serve as diagnostic biomarkers for idiopathic pulmonary fibrosis (IPF).
Everest Medicines Reports Promising Phase 1b/2a Results for EVER001 BTK Inhibitor in Primary Membranous Nephropathy
Everest Medicines presented positive Phase 1b/2a trial results for EVER001, a next-generation covalent reversible BTK inhibitor, showing significant efficacy in treating primary membranous nephropathy at the 62nd European Renal Association Congress.
Meta-Analysis Confirms Efficacy of Traditional Chinese Medicine Si-Shen-Wan for Treating IBS-D
A comprehensive meta-analysis of 34 randomized controlled trials involving 2,976 participants has validated the efficacy of Si-Shen-Wan (SSW) in treating diarrhea-predominant irritable bowel syndrome.
VivaVision's VVN461 Shows Promising Results in Phase 2 Trial for Non-Infectious Anterior Uveitis
VivaVision Biotech's dual JAK1/TYK2 inhibitor VVN461 demonstrated non-inferior efficacy to prednisolone acetate in treating non-infectious anterior uveitis in a Phase 2 trial conducted across 10 clinical sites in China.